

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Barbara A. Gilchrest	Title:	Modulation of Telomere-Initiated Cell Signaling
App. No.:	10/553,001	Art Unit:	1635
Conf. No.:	9118	Examiner:	Zara, Jane J.
Filing Date:	July 24, 2006		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the reference listed on the attached Form PTO SB/08a. It is respectfully requested that this Information Disclosure Statement be entered and the document listed on attached Form PTO SB/08a be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement does not include a copy of cited U.S. patent pursuant to 37 C.F.R. 1.98(a)(2) .

The following U.S. Applications may be related to the above-identified application:

U.S. Application No. 08/467,012 filed June 6, 1995 (now U.S. Patent No. 5,955,059);
U.S. Application No. 09/048,927 filed March 26, 1998 (now U.S. Patent No. 6,147,056)
which is a continuation-in-part of U.S. Application No. 08/952,697;
U.S. Application No. 09/540,843 filed March 31, 2000 (now U.S. Patent No. 7,094,766)
which is a continuation-in-part of U.S. Application No. 08/952,697;
U.S. Application No. 10/122,633 filed April 12, 2002 (now U.S. Patent No. 7,033,829)
which is a continuation-in-part of PCT/US01/10162;
U.S. Application No. 11/195,088 filed August 1, 2005 which is a continuation-in-part of
U.S. Application No. 10/122,633;
U.S. Application No. 11/409,706 filed April 24, 2006 which is a continuation of U.S.
Application No. 10/122,633;
U.S. Application No. 12/709,378 filed February 19, 2010 which is a continuation of U.S.
Application 11/195,088;
U.S. Application No. 12/275,089 filed November 20, 2008 which is a continuation of
U.S. Application No. 11/195,088
U.S. Application No. 12/715,242 filed March 1, 2010 which is a continuation of U.S.
Application No. 11/195,088; and
U.S. Application No. 10/122,630 filed April 12, 2002 which is a continuation-in-part of
PCT/US01/10162.

Office actions issued in related U.S. applications are listed on the PTO-SB08B form and
a copy of each is submitted herewith.


No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any additional fees be deemed necessary and proper, the Commissioner is hereby authorized to deduct any such fees from Deposit Account 08-3038.

Respectfully submitted,

HOWREY LLP

Dated: September 24, 2010

By:


Kate G. Berezutskaya, Ph.D.
Registration No.: 53,984
Customer No.: 22930

HOWREY LLP
ATTN: Docketing Department
2941 Fairview Park Drive, Suite 200
Falls Church, VA 22042-2924
Facsimile No.: (703) 336-6950